Linear Scalability of CAR Lentivirus Production


Single-use bioreactors were first introduced about a decade ago and has since become the benchmark for cGMP acceptance in the biomanufacturing industry. Many single-use bioreactors such as stirred-tank reactors (STRs), can only support suspension cell lines. In the current market, there are only a few bioreactors that can perform large scale culture of adherent cell lines, one of which includes VaccixCell’s TideMotion® Bioreactors – CelCradle and TideCell®.

Chimeric Antigen Receptor T-cells (CAR-T) therapy is the latest new trend for cancer treatment. Given the rapid gain of interest, many groups are advancing their laboratory findings aggressively towards clinical phase with the need for large scale CAR-T production. One of the most common bioprocessing challenge remains in the inability to scaleup linearly. Whilst many parameters may be readily reproduced across scales, e.g., operating temperature and pH, others, such as dissolved oxygen transfer rate or shear stress, may not. Consequently, higher cost, effort and time will be required to re-optimize each scale-up. Such challenges and undesired conditions can easily be overcome by using TideMotion® bioreactors.

In this whitepaper, we focus on the linear scalability of CelCradle to TideCell® on transfection efficiency of HEK-293T using 4-plasmid lentiviral system to support large-scale LVV production.